Med BioGene Loss Declines in Advance of US Launch for LungExpress Dx

The Canadian firm reported no revenues, as it plans to launch its lung cancer panel this year in the US.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories